Clinical trials: 5-Fluorouracil
Endometrial Cancer, Gastric Cancer
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid…
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
- Trial name
- NCT05489211
- Testing
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil
- Where
- 96 sites in United States, Canada and 12 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
This is a multicenter, open-label, parallel-group, randomised, A phase IIb clinical trial of efficacy and safety of Ametumumab in combination with anti-PD-1 monoclonal antibody and FOLFIRI versus Ametumumab or Cetuximab in…
- Trial name
- NCT05684211
- Testing
- Ametumumab, Anti-PD-1 monoclonal antibody, Cetuximab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai Celfuture Biotech Co., Ltd.
Metastatic Colorectal Cancer (CRC)
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
This is a Phase 3, multicenter, randomized and double-blind study assessing the interchangeability between TRS003 and China-approved Bevacizumab® (also called China-approved Avastin) for first-line treatment of patients with…
- Trial name
- CRC (NCT05378867)
- Testing
- TRS003, China-approved Bevacizumab, mFOLFOX6
- Volunteers
- 126 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Locally Advanced or Metastatic Adenoca of the Biliary Tract
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.
- Trial name
- NCT00088270
- Testing
- OSI-7904L, 5-Fluorouracil/Leucovorin
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- OSI Pharmaceuticals
Stomach Neoplasm
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
Phase II: Primary objective: to select one of the 2 test arms (docetaxel with cisplatin, docetaxel with cisplatin and 5-FU), based primarily on complete responses, to advance to a phase III survival comparison against the CDDP +…
- Trial name
- NCT00290966
- Testing
- XRP6976
- Volunteers
- 610 people
- Sponsor
- Sanofi
Cancer, Gastro-Intestinal Intraepithelial Neoplasia
Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies
This single center, Phase 1b, prospective, dose limiting toxicity (DLT)-clearing study, will assess the safety and efficacy of intravenously administered PROMITIL in combination with FOLFOX in cancer patients with inoperable…
- Trial name
- NCT04729205
- Testing
- Promitil
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Colorectal Cancer
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
- Trial name
- NCT00111761
- Testing
- Irinotecan, Panitumumab, 5-Fluorouracil
- Volunteers
- 43 people
- Sponsor
- Amgen
Colorectal Cancer
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal…
- Trial name
- HORIZON I (NCT00278889)
- Testing
- AZD2171, 5-fluorouracil, Leucovorin
- Where
- 43 sites in Austria, Belgium and 7 more
- Volunteers
- 215 people
- Sponsor
- AstraZeneca
Gastric Cancer
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer.
- Trial name
- NCT02563054
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 45 sites in Argentina, Belize and 12 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Carcinoma, Hepatocellular
Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients
Primary: Overall Survival (OS) Secondary: Time to Tumor Progression (TTP) Response Rate (RR) Improvement of Quality of Life (QoL) Safety Secondary resection rate
- Trial name
- EACH (NCT00471965)
- Testing
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin
- Where
- 4 sites in China, South Korea and 2 more
- Volunteers
- 371 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Melanoma, Non-Small-Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
- Trial name
- NCT05355701
- Testing
- PF-07799933, binimetinib, cetuximab
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Solid Tumor, Advanced Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma).
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT07432295
- Testing
- Givastomig, Nivolumab, 5Fluorouracil
- Where
- 6 sites in United States, China and 1 more
- Volunteers
- 180 people
- Sponsor
- I-Mab Biopharma US Limited
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's…
- Trial name
- NCT02563002
- Testing
- mFOLFOX6, FOLFIRI, Pembrolizumab
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01470794
- Testing
- Toca 511 vector, Toca FC
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Tocagen Inc.
Metastatic Colorectal Cancer (mCRC)
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and…
- Trial name
- NCT07391566
- Testing
- LPM6690176, Bevacizumab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Luye Pharma Group Ltd.
Merkel Cell Carcinoma
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with MCC who have progressed on or after anti-PD-L1 therapy.
- Trial name
- NCT03167164
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.